Is AEON Biopharma struggling financially?

Yes, by its own account. AEON Biopharma told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector: Biotech/Pharma
Market cap: $9.6M
Source filing: 10-Q 14 May 2026
Balance sheet: 30 Jun 2026

Cash runway

2months

If the burn speeds up

Empty by Aug 2026
3months

If it eases off

Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.4M

Cash burned over the last 12 months

$17.3M

What AEON Biopharma told the SEC

…the use of equity as a source of financing would dilute existing shareholders. As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued. The preparation of these condensed…

AEON Biopharma, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

503.4% share-count increase The company issued stock. Each share now owns 83.4% less of the business than a year ago, before any change in the price.
Cash burn is narrowing It is spending 55% less cash per year than it was, so the runway above is lengthening rather than shortening.

Cash runway

The runway math

What AEON Biopharma told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt